ClinicalTrials.gg
RecruitingNCT07214376The PULSE-LHDUpdated Nov 10, 2026

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

An interventional study of Pulmonary Artery Denervation (PADN) and Sham procedure control in Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction and Hypertension, sponsored by Pulnovo Medical, Inc.. Recruiting at 19 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Pulnovo Medical, Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 10, 2026First site in ChinaStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
750
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 397 studies in Hypertension, Pulmonary with a site in United States — 72 open to participants now, 86 under way, 9 of them phase 3. Hypertension, Pulmonary · United States.

Planned enrollment
7th of 286
750 · median 30
Started
2026
with 23 others
No phase
42 of 397
12 open now
Primary completion
2029-12
later than 71 of 84 live
Registered
373rd of 397
by date

Among the 397 studies in Hypertension, Pulmonary with a site in United States, this one is the 7th largest by planned enrollment of the 286 interventional ones that give a count, is one of 24 that started in 2026, is one of 42 with no phase, reaches primary completion later than 71 of the 84 other live ones, and was the 373rd registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

72 of the 397 studies in Hypertension, Pulmonary with a site in United States are open now. Recruiting first, the newest first:

66 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Hypertension, Pulmonary with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.)

Participants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.

Read the detailed description

Roll-in Subjects:

Prior to enrollment of the first randomized subject at each site, up to two roll-in subjects per operator (maximum 2 operators per site) who meet all eligibility criteria for the randomized trial may be enrolled. Roll-in subjects will receive PADN plus GDMT. Roll-in subjects will undergo all protocol-specified assessments. The sponsor will determine when each operator has achieved acceptable experience with the PADN procedure to advance to the randomized trial, after which no further roll-in patients will be enrolled. Operators who have performed ≥3 prior PADN procedures may not need to enroll a roll-in patient prior to beginning randomization.

Randomized Subjects:

Subjects with CpcPH due to LHD who meet all eligibility criteria will be randomized in a 1:1 ratio (stratified by investigational site and by core laboratory assessed LVEF [≤40% vs >40%]) to one of the two treatment arms:

  1. Intervention: PADN plus GDMT
  2. Control: Placebo-procedure plus GDMT Subjects will undergo clinical follow-up at 1, 6, 12, 24 and 36 months. At 24 months, control subjects who have experienced a primary efficacy endpoint event and who still meet all eligibility criteria will be offered the opportunity to cross over to the PADN plus GDMT group.
03

Conditions studied

  • Pulmonary Hypertension
  • Heart Failure With Reduced Ejection Fraction
  • Hypertension
  • Vascular Diseases
  • Cardiovascular Diseases
  • Heart Failure
  • Heart Failure With Preserved Ejection Fraction
  • Heart Failure With Mid Range Ejection Fraction

Keywords

  • Pulmonary Artery Denervation
  • Pulmonary Hypertension Due to Left Heart Disease
  • Heart Failure
  • pulmonary hypertension
  • left heart failure
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 and ≤85 years of age
  2. Subject is diagnosed with chronic HF due to left-sided heart disease for at least 6 months prior to screening (regardless of ), and remains symptomatic despite maximally tolerated class I GDMT for left heart failure and CRT as appropriate per US or EU guidelines according to region of enrollment
  3. Subject is clinically stable, defined as:

    • No hospitalizations for heart failure for at least 1 month; no major changes in societal guideline-recommended class I oral GDMT for left heart failure for at least 1 month; no CRT or ICD implant in the prior 3 months; and no anticipated major changes in any HF-GDMT (other than possibly diuretic dose) or planned cardiac rhythm management device implantation after the procedure
    • SBP is ≥90 and ≤160 mmHg and resting HR is ≥50 and ≤100 bpm (≤110 bpm for atrial fibrillation)
  4. PASP (RVSP) is ≥30 mmHg on the baseline TTE.
  5. Subject has (NYHA) class II, III or IVa symptoms (IVa is defined as symptoms with minimal exertion or at rest, but the patient is able to ambulate and does not require continuous intravenous medications).
  6. Subject has 6MWD at baseline ranging from 100 to 450 m limited by dyspnea or fatigue and not orthopedic or other non-HF-related issues
  7. Subject has NT-proBNP ≥600 pg/mL for patients with LVEF ≤40% or ≥200 pg/mL for patients with LVEF >40% at the time of screening (a central lab will be made available for sites that cannot measure NT-proBNP)
  8. Subject is able and willing to follow all aspects of the research protocol including medication compliance and follow-up visits and testing.
  9. Subject or the subject's legally designated representative signs an IRB/EC approved form prior to study participation.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a of less than 1 year due to non-cardiovascular causes.
  2. Subject has known hypertrophic cardiomyopathy with either left ventricular (LV) outflow tract obstruction or systolic anterior motion (SAM) of the anterior leaflet of the mitral valve; pericardial disease; or infiltrative or active inflammatory myocardial disease, including known amyloidosis
  3. Subject has severe stenosis or regurgitation of any heart valve, moderate or severe stenosis of the aortic valve, or any degree of stenosis of the pulmonic valve
  4. Subject has symptomatic carotid stenosis, or (TIA) or stroke in the prior 30 days or any prior stroke with a permanent residual deficit with modified Rankin Scale (mRS) score ≥4
  5. Subject has any prior intracranial hemorrhage with or without a residual deficit, or any known intracranial pathology pre-disposing to bleeding (e.g. mass, AV fistula, aneurysm, etc.)
  6. Subjects with a known bleeding diathesis or who will refuse blood transfusions
  7. Subjects allergic to heparin (including heparin induced thrombocytopenia), unless bivalirudin or argatroban can be used for procedural anticoagulation
  8. Subjects with life threatening allergy to contrast dye that cannot be adequately pre-medicated, or any prior contrast-related anaphylaxis
  9. Subject has congenital heart disease other than mitral valve prolapse or a PFO
  10. Subject had coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) in the prior 6 months or is anticipated to undergo CABG or PCI within 12 months after randomization.
  11. Subject has any pacemaker with an intracardiac sensing or pacing lead or wire implanted in the prior 3 months, or CardioMEMS HF System or other intracardiac pressure monitoring system, or cardiac contractility modulation system or baroreceptor activation therapy implanted within the prior 3 months, or any plans to implant any of these devices within 12 months after the procedure.
  12. Subject has undergone atrial fibrillation ablation within the prior 6 months or is anticipated to undergo atrial fibrillation ablation within 12 months after randomization.
  13. Subject has undergone heart valve surgery or transcatheter valve intervention within the prior 6 months or is anticipated to undergo heart valve surgery or transcatheter valve intervention (e.g., valve repair or replacement, valvuloplasty) within 12 months after randomization.
  14. Subject has any tricuspid or pulmonic valve implants (implanted annuloplasty rings are allowed).
  15. Subject has an inferior vena cava (IVC) filter implant.
  16. Subject has received a prior heart or heart-lung transplantation or is listed for heart or heart-lung transplantation or is anticipated to receive a ventricular assist device (VAD) implant within 6 months after randomization.
  17. Subjects with intracardiac thrombus on TTE.
  18. Subjects with pericardial effusion ≥10 mm on TTE
  19. Subject's PH is predominantly due to WHO Group 1, 3, 4, or 5. Note: Multifactorial features of PH may be present, but the predominant diagnosis must be WHO Group 2 CpcPH.
  20. Subject has been treated with any group 1 PAH-targeted drugs, including sotatercept, within the prior month or is planned to receive such therapy after randomization.
  21. Subject is anticipated to undergo any surgery within 6 months after randomization (other than minor surgeries requiring only local anesthesia).
  22. Subject has severe renal insufficiency ( \<30 mL/min/1.73m2 by the CKD-EPI formula, or on dialysis).
  23. Subject has severe liver insufficiency ( classification C).
  24. Subject has count \<100 × 109/L.
  25. Subject has systemic inflammatory or other disease requiring long-term use of oral or .
  26. Subject has active infection requiring oral or intravenous antibiotics.
  27. Subject has a (BMI) >45 kg/m².
  28. Subjects with severe respiratory disease, defined as any disorder of the respiratory system with diffusing capacity of the lungs for carbon monoxide (DLCO) \<40% AND total lung capacity (TLC) \<60% AND (FEV1) \<70% by plethysmography; OR who require ambulatory or long-term oxygen therapy
  29. Subject has known severe untreated sleep apnea. Note: Subjects with sleep apnea treated with CPAP/BiPAP for at least the prior 3 months are not excluded.
  30. Subjects with pulmonary embolism or deep vein thrombosis in the prior 6 months.
  31. Subject is a pregnant or breastfeeding woman, or a woman planning to become pregnant within one year. Women of must have a negative pregnancy test within 1 week of randomization.
  32. Subject is participating in another clinical trial of an drug or device that has not reached its primary endpoint.
  33. Subject has severe cachexia/frailty, substance abuse, or any other condition that the investigator believes may affect the subject's ability to comply with or complete all the study requirements including follow-up visits.
  34. Subject is a member of a vulnerable population who, in the judgment of the investigator, is unable to give for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. This may include individuals with mental disability, children, impoverished persons, persons in prisons, persons in emergency situations, homeless persons, nomads, refugees, and those incapable of giving informed consent. Vulnerable populations may also include members of a group with a hierarchical structure such as university students, subordinate hospital and laboratory personnel, employees of the Sponsor, members of the armed forces, and persons kept in detention.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
750 participants (estimated)

Study arms

  • Experimental
    Pulmonary Artery Denervation (PADN)

    PADN plus GDMT

    Device: Pulmonary Artery Denervation (PADN)

  • Active comparator
    Control

    Placebo-procedure plus GDMT

    Device: Sham procedure control

Interventions

  • DevicePulmonary Artery Denervation (PADN)

    In patients randomized to Intervention, a Contrast pulmonary artery (PA) angiography will be performed to identify the pulmonary artery bifurcation and measure the PA diameter. Once the anatomy is deemed suitable, a radiofrequency ablation catheter will be introduced into the ostium of the left PA and the distal bifurcation of the main PA. The catheter will be maneuvered within the PA to deliver energy circumferentially, ensuring tight electrode contact with the endovascular surface. Approximately three ablations will be performed at a target temperature of 50 °C (range 45-55 °C) for 120 seconds each at both the left PA ostium and the distal main PA bifurcation. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)

  • DeviceSham procedure control

    In patients randomized to a placebo-procedure, a script will be followed for approximately 20 minutes to simulate the PADN procedure. All patients enrolled in this clinical study will following the Guideline-Directed Medical Therapy (GDMT)

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint

    Composite of Major Heart Failure Events (MHFE). Based on a time-to-first event analysis at 24-month follow-up evaluated when the last enrolled patient reaches 12-month follow-up: 1. Cardiovascular death; 2. Heart transplantation or durable left ventricular assist device (LVAD) implantation; 3.HF hospitalizations; 4. Outpatient worsening HF events

    Time frame: Immediately after the randomization to last enrolled patient reaches 12-month follow-up

  2. Primary Safety Endpoint

    Composite of Device-related or Procedre-related Major Adverse Events (MAEs) in the treatment group compared with a performance goal

    Time frame: 30-days

Secondary outcomes

  1. Cumulative incidence of Major Heart Failure Events

    All the following events as following: 1. Cardiovascular death; 2.Heart transplantation or durable left ventricular assist device (LVAD) implantation; 3.HF hospitalizations ; 4.Outpatient worsening HF events

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  2. Outpatient worsening HF events

    Number of outpatients requiring intravenous medication (inotropes, diuretics or vasodilators) due to worsening of heart failure

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  3. All cardiovascular hospitalizations

    Number of patients with cardiovascular hospitalizations

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  4. N-terminal pro-B-type natriuretic peptide (NT-proBNP)

    Changes in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline

    Time frame: 6 months, 12 months, 24 months, and 36 months

  5. 6 minute walk distance(6MWD)

    6 minute walk distance(6MWD) difference from baseline

    Time frame: 6 months, 12 months, 24 months, and 36 months

  6. Kansas City Cardiomyopathy Questionnaire (KCCQ)

    The KCCQ is a self-administered, questionnaire to provide a better description of quality of life in patients with heart failure. The overall summary score range from 0 to 100, higher score means higher quality of life. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score from baseline to 30 days and 6, 12, 24, and 36 months than baseline

    Time frame: 6 months, 12 months, 24 months, and 36 months

  7. durable left ventricular assist device (LVAD) implantation

    durable left ventricular assist device (LVAD) implantation (time to first and all events, including recurrent events)

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  8. heart transplantation

    number of heart transplantation (time to first event)

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  9. Durable LVAD implantation

    number of durable LVAD implantation (time to first event)

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  10. Cardiovascular death

    number of cardiovascular death

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  11. Atrial septostomy

    number of atrial septostomy (time to first event)

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  12. HF hospitalizations

    number of HF hospitalizations (time to first and all events, including recurrent events)

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

  13. Atrial shunt placement

    Number of atrial shunt placement for all the subjects (time to first event)

    Time frame: 30days, 6 months, 12 months, 24 months, and 36 months

Other outcomes

  1. Device-related or Procedure-related Major Adverse Events

    Composite of Device-related or Procedure-related Major Adverse Events (MAE) in the treatment group compared with a Performance Goal, defined as the composite of: 1. All-cause mortality; 2.Deep venous thrombosis or pulmonary embolism 3.Perforation or dissection of the pulmonary artery requiring surgical treatment ; 4.Pulmonary artery aneurysm; 5. Pulmonary artery stenosis; 6.Hemoptysis requiring surgical treatment; 7.Left recurrent laryngeal nerve injury; 8. Major vascular complications; 9.BARC type 3 or 5 bleeding; 10.Infection requiring intravenous antibiotics; 11.Endotracheal intubation; 12.Permanent implantation of a pacemaker or defibrillator

    Time frame: 30 days, 6 months, 12 months, 24 months, and 36 months

07

Study locations

18 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2029, 40 months after the start.

Of 150 interventional studies with no phase under Hypertension, Pulmonary, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 48. This study's planned 40 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Aug 2026, on Oct 1, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2025
First posted
Oct 9, 2025
StartActual
Aug 21, 2026was Jul 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2031
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
13 sites added — first site in China
Show 13 added (9 United States, 4 China)
  • Boston Medical Center · Boston, United States
  • North Shore University Hospital · Manhasset, United States
  • Mount Sinai Morningside · New York, United States
  • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
  • Xiamen Cardiovascular Hospital Xiamen University · Xiamen, China
  • Nanjing First Hospital · Nanjing, China
  • Qilu Hospital of Shandong University · Jinan, China
  • Yale University · New Haven, United States
  • Cleveland Clinic Florida - Weston · Weston, United States
  • Weill Cornell Medical Center · New York, United States
  • NewYork-Presbyterian Hospital/Columbia University Irving Medical Center · New York, United States
  • Lankenau Institute for Medical Research · Wynnewood, United States
  • Washington Hospital Center · Washington D.C., United States
across 4 updates, Oct 1, 2026 – Nov 10, 2026
Start date
Jul 30, 2026→Aug 21, 2026 (actual)
Oct 1, 2026
Show all 4 updates
  1. Nov 10, 2026
    1 site added
    Show site
    • Washington Hospital Center · Washington D.C., United States
  2. Oct 20, 2026
    2 sites added
    Show 2 added (2 United States)
    • NewYork-Presbyterian Hospital/Columbia University Irving Medical Center · New York, United States
    • Lankenau Institute for Medical Research · Wynnewood, United States
  3. Oct 6, 2026
    3 sites added
    Show 3 added (3 United States)
    • Yale University · New Haven, United States
    • Cleveland Clinic Florida - Weston · Weston, United States
    • Weill Cornell Medical Center · New York, United States
    + 1 other change: verification date
  4. Oct 1, 2026
    7 sites added — first site in China
    Show 7 added (4 China, 3 United States)
    • Boston Medical Center · Boston, United States
    • North Shore University Hospital · Manhasset, United States
    • Mount Sinai Morningside · New York, United States
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
    • Xiamen Cardiovascular Hospital Xiamen University · Xiamen, China
    • Nanjing First Hospital · Nanjing, China
    • Qilu Hospital of Shandong University · Jinan, China
    Start date Jul 30, 2026→Aug 21, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07214376
Lead sponsor
Pulnovo Medical, Inc.
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Aug 21, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

MOFFETT LAURA MARY GINTANT
Contact
laura.moffett@pulnovomed.com
+1 952 303 2821
Mark Gu
Contact
mark.g@pulnovomed.com
+08 13774217349
Gregg W. Stone
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion